The DOI matches its Crossref record; 859 of the 859 references it cites were found in a registry or an index.
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Open accessAbstract
Receptor tyrosine kinases (RTKs), a category of transmembrane receptors, have gained significant clinical attention in oncology due to their central role in cancer pathogenesis. Genetic alterations, including mutations, amplifications, and overexpression of certain RTKs, are critical in creating environments conducive to tumor development. Following their discovery, extensive research has revealed how RTK dysregulation contributes to oncogenesis, with many cancer subtypes showing dependency on aberrant RTK signaling for their proliferation, survival and progression. These findings paved the way for targeted therapies that aim to inhibit crucial biological pathways in cancer. As a result, RTKs have emerged as primary targets in anticancer therapeutic development. Over the past two decades, this has led to the synthesis and clinical validation of numerous small molecule tyrosine kinase inhibitors (TKIs), now effectively utilized in treating various cancer types. In this manuscript we aim to provide a comprehensive understanding of the RTKs in the context of cancer. We explored the various alterations and overexpression of specific receptors across different malignancies, with special attention dedicated to the examination of current RTK inhibitors, highlighting their role as potential targeted therapies. By integrating the latest research findings and clinical evidence, we seek to elucidate the pivotal role of RTKs in cancer biology and the therapeutic efficacy of RTK inhibition with promising treatment outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 601–800 of 859
Lauring, J. D., Cosgrove, D., Fontana, S. C., Gustin, J. P., Konishi, H., Abukhdeir, A. M., Garay, J. P., Mohseni, M., Wang, G., Higgins, M. J., et al. (2010) · Oncogene · doi:10.1038/onc.2009.516 · Cited by 58
The role of HGF/c-MET signaling pathway in lymphoma
Lam, B., Dai, L., & Qin, Z. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0366-y · Cited by 58
Roy, J. P., Halford, M. M., & Stacker, S. A. (2018) · Growth Factors · doi:10.1080/08977194.2018.1472089 · Cited by 58
Desai, A. P., & Lovly, C. M. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-708 · Cited by 58
An Update on the Biology of RAS/RAF Mutations in Colorectal Cancer
Nandan, M. O., & Yang, V. W. (2011) · Current Colorectal Cancer Reports · doi:10.1007/s11888-011-0086-1 · Cited by 57
Bhalla, S., Fattah, F. J., Ahn, C. W., Williams, J. N., Macchiaroli, A., Padro, J., Pogue, M., Dowell, J. E., Putnam, W. C., McCracken, N. W., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107291 · Cited by 57
Du, X. L., Xia, R., Burau, K. D., & Liu, C. (2010) · Medical Oncology · doi:10.1007/s12032-010-9717-7 · Cited by 56
Hamberg, P., de Jong, F. A., Boonstra, J. G., van Doorn, J., Verweij, J., & Sleijfer, S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5318 · Cited by 56
Xia, W., Bacus, S. S., Husain, I., Liu, L.-H., Zhao, S., Liu, Z., Moseley, M. A., Thompson, J. W., Chen, F. L., Koch, K. M., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1041 · Cited by 55
Hofmann, S. R., Lam, A. Q., Frank, S., Zhou, Y., Ramos, H. L., Kanno, Y., Agnello, D., Youle, R. J., & O’Shea, J. J. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.11.5039-5049.2004 · Cited by 55
Muscle-Specific Kinase Myasthenia Gravis
Borges, L. S., & Richman, D. P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00707 · Cited by 55
He, M., Yang, H., Shi, H., Hu, Y., Chang, C., Liu, S., & Yeh, S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.028 · Cited by 55
Xu, J., Wang, J., & Zhang, S. (2017) · Oncotarget · doi:10.18632/oncotarget.21164 · Cited by 54
Drilon, A. E. D. C., Zhai, D., Rogers, E., Deng, W., Zhang, X., Ung, J., Lee, D. K., Rodón, L., Graber, A., Zimmerman, Z. F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.3616 · Cited by 54
Perrinjaquet, M., Vilar, M., & Ibáñez, C. F. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.144923 · Cited by 53
Boyle, E. M., Ashby, C., Tytarenko, R. G., Deshpande, S., Wang, H., Wang, Y., Rosenthal, A., Sawyer, J. R., Tian, E., Flynt, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1507 · Cited by 53
Chen, R., Li, Q., Xu, S., Ye, C., Tian, T., Jiang, Q., Shan, J., & Ruan, J. (2022) · Cancer Cell International · doi:10.1186/s12935-021-02435-4 · Cited by 53
Gas6/AXL pathway: immunological landscape and therapeutic potential
Zhai, X., Pu, D., Wang, R.-L., Zhang, J., Lin, Y., Wang, Y., Zhai, N., Peng, X., Zhou, Q., & Li, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1121130 · Cited by 53
Chen, X., Xu, H., Chen, X., Xu, T., Tian, Y., Wang, D., Guo, F., Wang, K., Jin, G., Li, X., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01773-9 · Cited by 53
Dai, J., Kong, Y., Si, L., Chi, Z., Cui, C., Sheng, X., Mao, L., Li, S., Lian, B., Yang, R., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1266 · Cited by 52
Nakamura, M., Ono, Y. J., Kanemura, M., Tanaka, T., Hayashi, M., Terai, Y., & Ohmichi, M. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.08.010 · Cited by 51
Wang, L., & Wang, W. (2020) · Oncology Reports · doi:10.3892/or.2020.7851 · Cited by 51
Nanomedicine of tyrosine kinase inhibitors
Šmídová, V., Michálek, P., Goliášová, Z., Eckschlager, T., Hodek, P., Adam, V., & Heger, Z. (2020) · Theranostics · doi:10.7150/thno.48662 · Cited by 51
Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models
Chew, N. J., Sian, T. C. C. L. K., Nguyen, E. V., Shin, S., Yang, J., Hui, M. N., Deng, N., McLean, C., Welm, A. L., Lim, E., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01461-4 · Cited by 50
Khurshid, S., Montes, M., Comiskey, D. F., Shane, B., Matsa, E., Jung, F., Brown, C., Bid, H. K., Wang, R., Houghton, P. J., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-021-00245-5 · Cited by 50
Tang, R., Langdon, W. Y., & Zhang, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.971162 · Cited by 50
Nakai, Y., Nonomura, N., Oka, D., Shiba, M., Arai, Y., Nakayama, M., Inoue, H., Nishimura, K., Aozasa, K., Mizutani, Y., et al. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.042 · Cited by 49
Vella, V., & Malaguarnera, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123814 · Cited by 49
Lee, J., Kim, H. S., Lee, B., Kim, H. K., Sun, J., Ahn, J. S., Ahn, M., Park, K., & Lee, S. (2020) · Cancer · doi:10.1002/cncr.32809 · Cited by 49
Miyazaki, I., Odintsov, I., Ishida, K., Lui, A. J. W., Kato, M., Suzuki, T., Zhang, T., Wakayama, K., Kurth, R. I., Cheng, R., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00630-y · Cited by 49
Xie, S., Li, Y., Li, X., Wang, L., Yang, N. Y., Wang, Y., & Wei, H. (2015) · Oncotarget · doi:10.18632/oncotarget.3280 · Cited by 48
Hansen, T. F., Sørensen, F. B., Spindler, K. G., Olsen, D. A., Andersen, R. F., Lindebjerg, J., Brandslund, I., & Jakobsen, A. K. M. (2010) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-009-0878-8 · Cited by 48
Nestin negatively regulates postsynaptic differentiation of the neuromuscular synapse
Yang, J., Dominguez, B., de Winter, F., Gould, T. W., Eriksson, J., & Lee, K. (2011) · Nature Neuroscience · doi:10.1038/nn.2747 · Cited by 48
Activating mutation in MET oncogene in familial colorectal cancer
Neklason, D. W., Done, M. W., Sargent, N. R., Schwartz, A. G., Anton‐Culver, H., Griffin, C. A., Ahnen, D. J., Schildkraut, J. M., Tomlinson, G. E., Strong, L. C., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-424 · Cited by 48
Toledo, R. A., Garralda, E., Mitsi, M., Pons, T., Monsech, J., Vega, E., Otero, Á., Albarran, M. I., Baños, N., Durán, Y., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0103 · Cited by 48
V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer
Gao, Y., Maria, A., Na, N., Paula, A. D. C., Gorelick, A. N., Hechtman, J. F., Carson, J., Lefkowitz, R. A., Weigelt, B., Taylor, B. S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0356 · Cited by 48
Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
Qunaj, L., May, M. S., Neugut, A. I., & Herzberg, B. O. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1252516 · Cited by 48
Mudduluru, G., Leupold, J. H., Ströbel, P., & Allgayer, H. (2010) · Biology of the Cell · doi:10.1042/bc20100094 · Cited by 47
Kim, Y., Li, Z., Apetri, M. M., Luo, B., Settleman, J. E., & Anderson, K. S. (2012) · Biochemistry · doi:10.1021/bi300476v · Cited by 47
Yeung, D. A., Shanker, N., Sohail, A., Weiss, B. A., Wang, C., Wellmerling, J. H., Das, S., Ganju, R. K., Miller, J. L. C., Herr, A. B., et al. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.11.015 · Cited by 47
Smorodinsky-Atias, K., Soudah, N., & Engelberg, D. (2020) · Cells · doi:10.3390/cells9010129 · Cited by 47
Two common disease-associated TYK2 variants impact exon splicing and TYK2 dosage
Li, Z., Rotival, M., Patin, É., Michel, F., & Pellegrini, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0225289 · Cited by 47
Rodríguez-Trillo, Á., Mosquera, N., Pena, C., Rivas-Tobío, F., Mera, A., Gonzalez, A., & Conde, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.555245 · Cited by 47
Ohgami, R. S., Ma, L., Monabati, A., Zehnder, J. L., & Arber, D. A. (2014) · Haematologica · doi:10.3324/haematol.2013.101543 · Cited by 46
Ras and Ras mutations in cancer
Rajasekharan, S., & Raman, T. (2013) · Open Life Sciences · doi:10.2478/s11535-013-0158-5 · Cited by 46
LMTK3 confers chemo-resistance in breast cancer
Stebbing, J., Shah, K., Lit, L. C., Gagliano, T., Ditsiou, A., Wang, T., Wendler, F., Simon, T., Szabó, K. S., O’Hanlon, T., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0197-0 · Cited by 46
Nakaoka, A., Nakahana, M., Inubushi, S., Akasaka, H., Salah, M., Kubota, H., Fujita, Y., Hassan, M., Mukumoto, N., Nishikawa, R., et al. (2021) · Oncology Reports · doi:10.3892/or.2021.7964 · Cited by 46
Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs)
Xu, J. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211042689 · Cited by 46
ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance
Yu, Z.-Q., Wang, M., Zhou, W., Mao, M.-X., Chen, Y., Li, N., Peng, X., Cai, J., & Cai, Z.-Q. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2085730 · Cited by 46
Structural insights into the assembly of the agrin/LRP4/MuSK signaling complex
Xie, T., Xu, G., Liu, Y., Quade, B., Lin, W., & Bai, X. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2300453120 · Cited by 46
Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma
Sweeney, P. L., Suri, Y., Basu, A., Koshkin, V. S., & Desai, A. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.89 · Cited by 46
Negative regulation of receptor tyrosine kinase signals
Fiorini, M., Alimandi, M., Fiorentino, L., Sala, G., & Segatto, O. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02116-0 · Cited by 45
A JAK2 Interdomain Linker Relays Epo Receptor Engagement Signals to Kinase Activation
Lequn, Z., Dong, H., Zhang, C. C., Kinch, L. N., Osawa, M., Iacovino, M., Grishin, N. V., Kyba, M., & Huang, L. J.-S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.011387 · Cited by 45
Aveic, S., & Tonini, G. P. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0341-2 · Cited by 45
Cardiotoxicity of Novel Targeted Hematological Therapies
Giudice, V., Vecchione, C., & Selleri, C. (2020) · Life · doi:10.3390/life10120344 · Cited by 45
AXL receptor tyrosine kinase as a therapeutic target in NSCLC
Bivona, T. G., & Okimoto, R. A. (2015) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s60438 · Cited by 44
Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer
Sobhani, N., Ianza, A., D’Angelo, A., Roviello, G., Giudici, F., Bortul, M., Zanconati, F., Bottin, C., & Generali, D. (2018) · Cells · doi:10.3390/cells7070076 · Cited by 44
Wang, Z., Wang, X., Wang, Z., Feng, Y., Jia, Y., Jiang, L., Xia, Y., Cao, J., & Liu, Y. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.20165 · Cited by 44
Role of fibroblast growth factor receptor 4 in cancer
Tang, S., Hao, Y., Yao Zong, Y. U. A. N., Liu, R. R., & Chen, Q. (2018) · Cancer Science · doi:10.1111/cas.13759 · Cited by 43
Fachi, M. M., Tonin, F. S., Leonart, L. P., Rotta, I., Fernández-Llimós, F., & Pontarolo, R. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13933 · Cited by 43
Hasan, M. K., Ghia, E. M., Rassenti, L. Z., Widhopf, G. F., & Kipps, T. J. (2020) · Leukemia · doi:10.1038/s41375-020-01055-7 · Cited by 43
Structural basis of cytokine-mediated activation of ALK family receptors
Munck, S. D., Provost, M., Kurikawa, M., Omori, I., Mukohyama, J., Félix, J., Bloch, Y., Abdel-Wahab, O. I., Bazán, J. F., Yoshimi, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03959-5 · Cited by 43
de Reyniès, A., Boige, V., Milano, G. A., Faivre, J., & Laurent‐Puig, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9186 · Cited by 42
Coco, S., Truini, A., Alama, A., Bello, M. G. D., Venè, R., Garuti, A., Carminati, E., Rijavec, E., Genova, C., Barletta, G., et al. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0344-7 · Cited by 42
Jin, J., Ryu, H. S., Lee, K. B., & Jang, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090247 · Cited by 42
STAT5 contributes to antiapoptosis in melanoma
Hassel, J. C., Winnemöller, D., Schartl, M., & Wellbrock, C. (2008) · Melanoma Research · doi:10.1097/cmr.0b013e32830ce7d7 · Cited by 42
ALK-Activating Homologous Mutations in LTK Induce Cellular Transformation
Roll, J. D., & Reuther, G. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031733 · Cited by 42
Guo, G., Qiu, X., Wang, S., Chen, Y., Rothman, P. B., Wang, Z., Chen, Y., Wang, G., & Chen, J.-L. (2010) · Oncogene · doi:10.1038/onc.2010.149 · Cited by 42
Decoding the Role of CD271 in Melanoma
Vidal, A., & Redmer, T. (2020) · Cancers · doi:10.3390/cancers12092460 · Cited by 42
MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression
Jiang, Y., Zhang, Y., Leung, J. Y., Fan, C., Popov, K. I., Su, S., Qian, J., Wang, X., Holtzhausen, A., Ubil, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09233-7 · Cited by 41
Insulin and epidermal growth factor receptor family members share parallel activation mechanisms
Ferguson, K. M., Hu, C., & Lemmon, M. A. (2020) · Protein Science · doi:10.1002/pro.3871 · Cited by 41
AKT mutant allele-specific activation dictates pharmacologic sensitivities
Shrestha-Bhattarai, T., Shamu, T., Gorelick, A. N., Chang, M. T., Chakravarty, D., Gavrila, E. I., Donoghue, M. T. A., Gao, J., Patel, S., Gao, S. P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29638-1 · Cited by 41
Desensitization to imatinib in patients with leukemia
Nelson, R. P., Cornetta, K. G., Ward, K. E., Ramanuja, S., Fausel, C., & Cripe, L. D. (2006) · Annals of Allergy Asthma & Immunology · doi:10.1016/s1081-1206(10)60016-6 · Cited by 40
Challenging role of Wnt5a and its signaling pathway in cancer metastasis (Review)
ZHU, N., Li, Q., Luo, Z., et al. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.1676 · Cited by 40
Degryse, S., Bornschein, S., de Bock, C. E., Leroy, E., Bempt, M. V., Demeyer, S., Jacobs, K., Geerdens, E., Gielen, O., Soulier, J., et al. (2017) · Blood · doi:10.1182/blood-2017-07-797597 · Cited by 40
Discoidin domain receptors: A promising target in melanoma
de Moura, C. R., Battistella, M., Sohail, A., Caudron, A., Feugeas, J. P., Podgorniak, M.-P., Pagès, C., Mazouz-Dorval, S., Marco, O., Ménashi, S., et al. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12809 · Cited by 40
Functional Consequences ofAXLSequence Variants in Hypogonadotropic Hypogonadism
Salian‐Mehta, S., Xu, M., Knox, A. J., Plummer, L., Slavov, D. B., Taylor, M. R. G., Bevers, S. G., Hodges, R. S., Crowley, W. F., & Wierman, M. E. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3426 · Cited by 39
Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib
Ravi, V., Sanford, E. M., Wang, W., Ross, J. S., Ramesh, N., Futreal, P. A., Patel, S., Stephens, P. J., Miller, V. A., & Ali, S. M. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0058 · Cited by 39
Khan, H. Y., Ge, J., Nagasaka, M., Aboukameel, A., Mpilla, G., Muqbil, I., Szlaczky, M., Chaker, M., Baloglu, E., Landesman, Y., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010237 · Cited by 39
AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations
Falcone, I., Conciatori, F., Bazzichetto, C., Bria, E., Carbognin, L., Malaguti, P., Ferretti, G., Cognetti, F., Milella, M., & Ciuffreda, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228419 · Cited by 39
Majo, S., & Auguste, P. (2021) · Cancers · doi:10.3390/cancers13071725 · Cited by 39
Takahashi, H., Sakakibara‐Konishi, J., Furuta, M., Shoji, T., Tsuji, K., Morinaga, D., Kikuchi, E., Kikuchi, J., Noguchi, T., Hatanaka, K. C., et al. (2022) · Cancer Science · doi:10.1111/cas.15674 · Cited by 39
Arora, S., Scott, A. M., & Janes, P. W. (2023) · Biomedicines · doi:10.3390/biomedicines11020315 · Cited by 39
MerTK is a novel therapeutic target in gastric cancer
Yi, J. H., Jang, J., Cho, J., Do, I., Hong, M. E., Kim, S. T., Kim, K., Lee, S., Park, S. H., Park, J. O., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3750 · Cited by 38
Chung, S., Tamura, K., Furihata, M., Uemura, M., Daigo, Y., Nasu, Y., Miki, T., Shuin, T., Fujioka, T., Nakamura, Y., et al. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01277.x · Cited by 38
Mechanisms of acquired resistance to afatinib clarified with liquid biopsy
Nakamura, T., Nakashima, C., Komiya, K., Kitera, K., Hirai, M., Kimura, S. H., & Sueoka‐Aragane, N. (2018) · PLoS ONE · doi:10.1371/journal.pone.0209384 · Cited by 38
Shi, Y., Fang, J., Hao, X., Zhang, S., Liu, Y., Wang, L., Chen, J., Hu, Y., Hang, X., Li, J., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00841-8 · Cited by 38
HMGA1 protein is a positive regulator of the insulin-like growth factor-I receptor gene
Aiello, A., Pandini, G., Sarfstein, R., Werner, H., Manfioletti, G., Vigneri, R., & Belfiore, A. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.050 · Cited by 37
Identification and characterization of two novel oncogenic mTOR mutations
Murugan, A. K., Liu, R., & Xing, M. (2019) · Oncogene · doi:10.1038/s41388-019-0787-5 · Cited by 37
LRP-1 Promotes Colon Cancer Cell Proliferation in 3D Collagen Matrices by Mediating DDR1 Endocytosis
Le, C., Bennasroune, A., Collin, G., Hachet, C., Lehrter, V., Rioult, D., Dedieu, S., Morjani, H., & Appert-Collin, A. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00412 · Cited by 37
Proteolytic Cleavage of Receptor Tyrosine Kinases
Huang, H. (2021) · Biomolecules · doi:10.3390/biom11050660 · Cited by 37
Shi, Y., Wu, S., Wang, K., Cang, S., Yao, W., Fan, Y., Wu, L., Huang, M., Li, X., Pan, Y., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.08.015 · Cited by 37
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer
Katayama, Y., Yamada, T., Tanimura, K., Tokuda, S., Morimoto, K., Hirai, S., Matsui, Y., Nakamura, R., Ishida, M., Kawachi, H., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00350-7 · Cited by 37
Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments
Chen, S., Tang, J., Liu, F., Li, W., Yan, T., Shangguan, D., Yang, N., & Liao, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1094764 · Cited by 37
Fachi, M. M., Tonin, F. S., Leonart, L. P., Aguiar, K. S., Lenzi, L., de Figueiredo, B. C., Fernández-Llimós, F., & Pontarolo, R. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.08.016 · Cited by 36
Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer
Wulf, A. M., Moreno, M. M., Paka, C. A., Rampasekova, A., & Liu, K. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111718 · Cited by 36
Hua, G., Zhang, X., Zhang, M., Wang, Q., Chen, X., Yu, R., Bao, H., Liu, J., Wu, X., Shao, Y., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2021.100337 · Cited by 36
Shi, Y., Li, B., Wu, L., Pan, Y., Pan, Z., Liu, Y., Fan, Y., Ji, Y., Fang, J., Shi, Q., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.05.011 · Cited by 36
Marín, A., Mamun, A. A., Patel, H. M., Akamatsu, H., Ye, D., Sudhan, D. R., Eli, L. D., Marcelain, K., Brown, B. P., Meiler, J., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3617 · Cited by 36
Discoidin domain receptors: a proteomic portrait
Iwai, L. K., Luczynski, M. T., & Huang, P. H. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1616-1 · Cited by 35
Receptor tyrosine kinase mutations in myeloid neoplasms
Gupta, R., Knight, C. L., & Bain, B. J. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03469.x · Cited by 35
Bahlawane, C., Eulenfeld, R., Wiesinger, M., Wang, J., Muller, A., Girod, A., Nazarov, P. V., Felsch, K., Vallar, L., Sauter, T., et al. (2015) · Cell Communication and Signaling · doi:10.1186/s12964-015-0096-8 · Cited by 35
Noeparast, A., Giron, P., Noor, A., Shahi, R. B., Brakeleer, S. D., Eggermont, C., Vandenplas, H., Boeckx, B., Lambrechts, D., Grève, J. D., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0866-7 · Cited by 35
Zhang, W., Yu, G., Zhang, H., Basyal, M., Ly, C., Yuan, B., Ruvolo, V. R., Piya, S., Bhattacharya, S., Zhang, Q., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.280884 · Cited by 35
Role of the planar cell polarity gene Protein tyrosine kinase 7 in neural tube defects in humans
Wang, M., Marco, P. D., Merello, E., Drapeau, P., Capra, V., & Kibar, Z. (2015) · Birth Defects Research Part A Clinical and Molecular Teratology · doi:10.1002/bdra.23422 · Cited by 34
Jeffers, M., Rao, M. S. R., Rulong, S., Jk, R., Subbarao, V., Hudson, E., Woude, G. F. V., & Resau, J. (1996) · PubMed · Cited by 34
Riedel, R. F., Fassunke, J., Tumbrink, H. L., Scheel, A. H., Heydt, C., Hieggelke, L., Scheffler, M., Heimsoeth, A., Nogová, L., Michels, S. Y. F., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.11.010 · Cited by 34
Metabolic rewiring drives resistance to targeted cancer therapy
Locasale, J. W. (2012) · Molecular Systems Biology · doi:10.1038/msb.2012.30 · Cited by 33
Nahm, C. B., Turchini, J., Jamieson, N. B., Moon, E. A., Sioson, L., Itchins, M., Arena, J., Colvin, E. K., Howell, V. M., Pavlakis, N., et al. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.10.050 · Cited by 33
Akt scaffold proteins: the key to controlling specificity of Akt signaling
Bao, F., Hao, P., An, S., Yang, Y., Liu, Y., Hao, Q., Ejaz, M., Guo, X., & Xu, T. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00146.2020 · Cited by 33
Kafri, N. A., & Hafizi, S. (2019) · Cancers · doi:10.3390/cancers11121843 · Cited by 32
The Ror-Family Receptors in Development, Tissue Regeneration and Age-Related Disease
Endo, M., Kamizaki, K., & Minami, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.891763 · Cited by 32
Cheng, D., Ge, K., Yao, X., Wang, B., Chen, R., Zhao, W., Fang, C., & Ji, M. Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1209947 · Cited by 32
Jaradat, S. K., Ayoub, N. M., Sharie, A. H. A., & Aldaod, J. M. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241234780 · Cited by 32
Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma
Wu, X., Yan, J., Dai, J., Ma, M., Tang, H., Yu, J., Xu, T., Yu, H., Si, L., Chi, Z., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.6608 · Cited by 31
The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma
Shi, C., Li, X., Wang, X., Ding, N., Ping, L., Shi, Y., Mi, L., Lai, Y., Song, Y., & Zhu, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0584-6 · Cited by 31
Soares, M. J., Pinto, M., Henrique, R., Vieira, J., Cerveira, N., Peixoto, A., Martins, A. T., Oliveira, J., Jerónimo, C., & Teixeira, M. R. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.43 · Cited by 30
Görgişen, G., Hapil, F. Z., Yilmaz, O., Çetin, Z., Pehlivanoğlu, S., Özbudak, İ. H., Erdoğan, A., & Özeş, O. N. (2019) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2017-0307 · Cited by 30
More than the sum of the parts: Toward full‐length receptor tyrosine kinase structures
Diwanji, D. C., Thaker, T. M., & Jura, N. (2019) · IUBMB Life · doi:10.1002/iub.2060 · Cited by 30
Lü, S., Zhang, Y., Zhang, G., Zhou, J., Cang, S., Cheng, Y., Wu, G., Cao, P., Lv, D., Jian, H., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.06.002 · Cited by 30
Genetic and Chemical Models of Colorectal Cancer in Mice
Nandan, M. O., & Yang, V. W. (2010) · Current Colorectal Cancer Reports · doi:10.1007/s11888-010-0046-1 · Cited by 29
Ptk7 and Mcc, Unfancied Components in Non-Canonical Wnt Signaling and Cancer
Dunn, N. R., & Tolwinski, N. S. (2016) · Cancers · doi:10.3390/cancers8070068 · Cited by 29
Famili, F., García-Pérez, L., Naber, B. A. E., Noordermeer, J. N., Fradkin, L. G., & Staal, F. J. T. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.380 · Cited by 29
Fu, Y., Chen, Y., Huang, J., Cai, Z., & Wang, Y. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00228.2019 · Cited by 29
LMTK3 promotes tumorigenesis in bladder cancer via the ERK/MAPK pathway
Jiang, T., Lu, X., Yang, F., Wang, M., Yang, H., & Xing, N. (2020) · FEBS Open Bio · doi:10.1002/2211-5463.12964 · Cited by 29
Jiang, K., Li, X., Wang, C., Hu, X., Wang, P., Tong, L., Tu, Y., Chen, B., Jin, T., Wang, T., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01795-8 · Cited by 29
Lim, M., Franses, J. W., Imperial, R. J. L., Majeed, U., Tsai, J., & Hsiehchen, D. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.01.023 · Cited by 29
Shi, Y., Chen, J., Zhang, H., Zhang, Z., Zhang, Y., Wang, Z., Zhang, S., Zhao, J., Liu, C., Wang, X., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02738-5 · Cited by 29
Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer
Yamaguchi, H., Kawazu, M., Yasuda, T., Soda, M., Ueno, T., Kojima, S., Yashiro, M., Yoshino, I., Ishikawa, Y., Sai, E., et al. (2015) · Cancer Science · doi:10.1111/cas.12828 · Cited by 28
Dou, X., Qin, Y., Huang, X., & Jiang, Q. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0109 · Cited by 28
Villarroel, A., del Valle‐Pérez, B., Fuertes, G., Curto, J., Ontiveros, N., de Herreros, A. G., & Duñach, M. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03221-2 · Cited by 28
Su, S., Liu, C.-H., Cheng, C.-L., Ho, C., Yang, T., Chen, K., Hsu, K.-H., Tseng, J., Chen, H., Chang, G., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00151 · Cited by 28
Colony Stimulating Factor 1 Receptor in Acute Myeloid Leukemia
Sletta, K. Y., Castells, O., & Gjertsen, B. T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.654817 · Cited by 28
Ancestral reconstruction reveals mechanisms of ERK regulatory evolution
Sang, D., Pinglay, S., Wiewiora, R., Selvan, M. E., Lou, H. J., Chodera, J. D., Turk, B. E., Gumus, Z. H., & Holt, L. J. (2019) · eLife · doi:10.7554/elife.38805 · Cited by 27
c-Kit Receptors as a Therapeutic Target in Cancer: Current Insights
Abdellateif, M. S., Bayoumi, A., & Mohammed, M. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s404648 · Cited by 27
The emerging role of receptor tyrosine kinase phase separation in cancer
Lin, C., Suen, K. M., Lidster, J. A., & Ladbury, J. E. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.09.002 · Cited by 27
Mariadoss, A. V. A., & Wang, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914895 · Cited by 27
Loaiza‐Bonilla, A., Jensen, C. E., Shroff, S. G., Furth, E. E., Bonilla-Reyes, P. A., Deik, A., & Morrissette, J. D. (2016) · Cureus · doi:10.7759/cureus.478 · Cited by 26
Ishibashi, M., Toyoshima, M., Zhang, X., Hasegawa‐Minato, J., Shigeta, S., Usui, T., Kemp, C. J., Grandori, C., Kitatani, K., & Yaegashi, N. (2018) · Scientific Reports · doi:10.1038/s41598-018-31069-2 · Cited by 26
Isnaldi, E., Garuti, A., Cirmena, G., Scabini, S., Rimini, E., Ferrando, L., Lia, M., Murialdo, R., Tixi, L., Carminati, E., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1879-2 · Cited by 26
Marta, G. N., Martins-Branco, D. A., Agostinetto, E., Bruzzone, M., Ceppi, M., Danielli, L., Lambertini, M., Kotecki, N., Awada, A. H., & de Azambuja, E. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100501 · Cited by 26
Pang, L., Gan, J., Tan, J., Huang, Y., Liao, J., Liang, W., Deng, P., & Fang, W. (2022) · Cancer · doi:10.1002/cncr.34451 · Cited by 26
Sayyah, J., Magis, A. T., Ostrov, D. A., Allan, R. W., Braylan, R. C., & Sayeski, P. P. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0279 · Cited by 25
Breaking Oncogene Addiction: Getting RTK/RAS-Mutated Cancers off the SOS
Sheffels, E., & Kortum, R. L. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00698 · Cited by 25
Bertol, B. C., Bales, E. S., Calhoun, J., Mayberry, A., Ledezma, M. L., Sams, S. B., Orlicky, D. J., Donadi, E. A., Haugen, B. R., & French, J. D. (2021) · Thyroid · doi:10.1089/thy.2021.0371 · Cited by 25
Noel, B. M., Ouellette, S. B., Marholz, L., Dickey, D., Navis, C., Yang, T.-Y., Nguyen, V., Parker, S. J., Bernlohr, D., Sachs, Z., et al. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00028 · Cited by 24
Identification of a Non-Gatekeeper Hot Spot for Drug-Resistant Mutations in mTOR Kinase
Tzung-Ju, W., Wang, X., Zhang, Y., Meng, L., Kerrigan, J. E., Burley, S. K., & Zheng, X. F. S. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.040 · Cited by 23
Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer
Ferguson, B. D., Tan, Y. C., Kanteti, R., Liu, R., Gayed, M. J., Vokes, E. E., Ferguson, M. K., Iafrate, A. J., Gill, P. S., & Salgia, R. (2015) · Scientific Reports · doi:10.1038/srep10641 · Cited by 23
Chen, X., Zhou, J., Zhao, J., Chen, J., Ma, S., & Zhou, J. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000011 · Cited by 23
Salzmann, M., Pawlowski, J., Loquai, C., Rafei-Shamsabadi, D. A., Meiß, F., Ugurel, S., Schadendorf, D., Meier, F. E., Enk, A., & Hassel, J. C. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.02.008 · Cited by 23
The Acute Lymphoblastic Leukemia-associated JAK2 L611S Mutant Induces Tumorigenesis in Nude Mice
Funakoshi‐Tago, M., Tago, K., Sumi, K., Abe, M., Aizu-Yokota, E., Oshio, T., Sonoda, Y., & Kasahara, T. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808879200 · Cited by 22
A High-Fat/High-Sucrose Diet Induces WNT4 Expression in Mouse Pancreatic β-cells
Kurita, Y., Ohki, T., Soejima, E., Yuan, X., Kakino, S., Wada, N., Hashinaga, T., Nakayama, H., Tani, J., Tajiri, Y., et al. (2018) · The Kurume Medical Journal · doi:10.2739/kurumemedj.ms652008 · Cited by 22
Identification of a novel oncogenic mutation of FGFR4 in gastric cancer
Futami, T., Kawase, T., Mori, K., Asaumi, M., Kihara, R., Shindoh, N., & Kuromitsu, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-51217-6 · Cited by 22
PanErbB-targeted CAR T-cell immunotherapy of head and neck cancer
Larcombe-Young, D., Papa, S., & Maher, J. F. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1786531 · Cited by 22
Naumann, N., Lübke, J., Baumann, S., Schwaab, J., Hoffmann, O. I., Kreil, S., Dangelo, V., Reiter, L., Bugert, P., Kristensen, T. K., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052562 · Cited by 22
Zhou, Q., Wu, L., Hu, P., An, T., Zhou, J., Zhang, L., Liu, X.-Q., Luo, F., Zheng, X., Cheng, Y., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2595 · Cited by 22
Scartozzi, M., Loretelli, C., Galizia, G., Mandolesi, A., Pistelli, M., Bittoni, A., Giampieri, R., Faloppi, L., Bianconi, M., Prete, M. D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038192 · Cited by 21
Rodríguez-Moreno, J. F., Apellániz-Ruiz, M., Roldán‐Romero, J. M., Durán, I., Beltrán, L., Montero‐Conde, C., Cascón, A., Robledo, M., García-Donás, J., & Rodríguez‐Antona, C. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.7018 · Cited by 21
Funkhouser, A., Strigenz, A. M., Blair, B. B., Miller, A. P., Shealy, J. C., Ewing, J. A., Martin, J., Funk, C. R., Edenfield, W. J., & Blenda, A. V. (2022) · Cancers · doi:10.3390/cancers14112781 · Cited by 21
Marguier, A., Laheurte, C., Lecoester, B., Malfroy, M., Boullerot, L., Renaudin, A., Seffar, E., Kumar, A., Nardin, C., Aubin, F., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.932298 · Cited by 21
Bugide, S., Edwards, Y. J. K., Gupta, R., Green, M. R., & Wajapeyee, N. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2218118120 · Cited by 21
Xie, X., Laster, K. V., Li, J., Nie, W., Yi, Y. W., Liu, K., Seong, Y., Dong, Z., & Kim, D. J. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04931-4 · Cited by 20
Downregulation of AP1S1 causes the lysosomal degradation of EGFR in non‐small cell lung cancer
Jeong, J., Hwang, Y. E., Lee, M., Keum, S., Song, S., Kim, J., Choi, J., & Rhee, S. (2023) · Journal of Cellular Physiology · doi:10.1002/jcp.31112 · Cited by 20
Characterization of the Phosphotyrosine-binding Domain of the Drosophila Shc Protein
Li, S., Lai, K. V., Gish, G. D., Parris, W. E., van der Geer, P., Forman-Kay, J. D., & Pawson, T. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.50.31855 · Cited by 19
Sun, L., Gao, L., Zhao, Y., Wang, Y., Xu, Q., Zheng, Y., Chen, J., He, W., & Wang, L. (2022) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892818666221201145810 · Cited by 19
Xiao, Z.-X., Li, M., Zhang, X., Rong, X., & Xu, H. (2023) · Oncology Reports · doi:10.3892/or.2023.8521 · Cited by 19
Heim, M. H. (2003) · Springer eBooks · doi:10.1007/978-94-017-3000-6_2 · Cited by 18
Jiang, L., Huang, J., Morehouse, C., Zhu, W., Korolevich, S., Sui, D., Ge, X., Lehmann, K. P., Liu, Z., Kiefer, C. M., et al. (2013) · Cancer Genetics · doi:10.1016/j.cancergen.2013.09.004 · Cited by 18
The Road Less Traveled: A Guide to Metastatic ROS1-Rearranged Non–Small-Cell Lung Cancer
Almquist, D., & Ernani, V. (2020) · JCO Oncology Practice · doi:10.1200/op.20.00819 · Cited by 18
The multifaceted role of lemur tyrosine kinase 3 in health and disease
Ditsiou, A., Gagliano, T., Samuels, M. E., Vella, V., Tolias, C. M., & Giamas, G. (2021) · Open Biology · doi:10.1098/rsob.210218 · Cited by 18
Exosomal non-coding RNAs-mediated EGFR-TKIs resistance in NSCLC with EGFR mutation
Cheng, D., Wang, B., Wu, L., Chen, R., Zhao, W., Fang, C., & Ji, M. (2023) · Medical Oncology · doi:10.1007/s12032-023-02125-3 · Cited by 18
Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer
Veiga, R. N., de Azevedo, A. L. K., de Oliveira, J. C., & Gradia, D. F. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02431-x · Cited by 18
Bencze, J., Szarka, M., Bencs, V., Szabó, R. N., Smajda, M., Aarsland, D., & Hortobágyi, T. (2019) · Scientific Reports · doi:10.1038/s41598-019-53638-9 · Cited by 17
Grillo, E., Corsini, M., Ravelli, C., Somma, M. D., Zammataro, L. A., Monti, E., Presta, M., & Mitola, S. M. F. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.09.027 · Cited by 17
Grillo, E., Corsini, M., Ravelli, C., Zammataro, L. A., Bacci, M., Morandi, A., Monti, E., Presta, M., & Mitola, S. M. F. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.03.007 · Cited by 17
c-Met: A Promising Therapeutic Target in Bladder Cancer
Feng, Y., Yang, Z., & Xu, X. (2022) · Cancer Management and Research · doi:10.2147/cmar.s369175 · Cited by 17
An extracellular receptor tyrosine kinase motif orchestrating intracellular STAT activation
Vaparanta, K. M., Jokilammi, A., Tamirat, M. Z., Merilahti, J. A. M., Salokas, K., Varjosalo, M. T., Ivaska, J., Johnson, M. S., & Elenius, K. (2022) · Nature Communications · doi:10.1038/s41467-022-34539-4 · Cited by 17
Balmanno, K., Kidger, A. M., Byrne, D. P., Sale, M. J., Nassman, N., Eyers, P. A., & Cook, S. J. (2023) · Biochemical Journal · doi:10.1042/bcj20220598 · Cited by 17
Lee, K., Lai, T., Lee, W.-J., Chen, Y.-C., Ho, K., Hung, W.-Y., Yang, Y., Chan, M., Hsieh, F.-K., Chung, C., et al. (2023) · Cancers · doi:10.3390/cancers15133288 · Cited by 17
Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
Qin, A., Qin, Y. H., Lee, J. K., Musket, A., Ying, M., Krenciute, G., Marincola, F. M., Yao, Z. Q., Musich, P. R., & Xie, Q. R. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04521-9 · Cited by 17
Li, Y., Wang, Y., Zhong, S., Rong, Z., Ren, Y., Li, Z., Zhang, S., Chang, Z., & Liu, L. (2009) · Molecules and Cells · doi:10.1007/s10059-009-0003-5 · Cited by 16
Kubasch, A. S., Péterlin, P., Cluzeau, T., Götze, K. S., Sockel, K., Teipel, R., Jentzsch, M., Attalah, H. L., Sébert, M., Chermat, F., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02029-1 · Cited by 16
MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF
Kondo, N., Utsumi, T., Shimizu, Y., Takemoto, A., Oh‐hara, T., Uchibori, K., Subat-Motoshi, S., Ninomiya, H., Takeuchi, K., Nishio, M., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.173688 · Cited by 16
Ding, X., Jiang, Q.-B., Li, R., Chen, S., & Zhang, S. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.04.016 · Cited by 15
Receptor Tyrosine Kinase Signal Transduction and the Molecular Basis of Signalling Specificity
MEYTS, P. D. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2_4 · Cited by 15
Sun, X., Song, Q., He, L., Yan, L., Liu, J., Zhang, Q., & Yu, Q. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0735 · Cited by 15
Heliste, J., Jokilammi, A., Paatero, I., Chakroborty, D., Stark, C., Savunen, T., Laaksonen, M., & Elenius, K. (2018) · BMC Cardiovascular Disorders · doi:10.1186/s12872-018-0933-y · Cited by 15
Bonfil, R. D., Chen, W., Vranić, S., Sohail, A., Shi, D., Jang, H., Kim, H.-R., Prunotto, M., & Fridman, R. A. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02206-1 · Cited by 15
Taniguchi, H., Akagi, K., Dotsu, Y., Yamada, T., Ono, S., Imamura, E., Gyotoku, H., Takemoto, S., Yamaguchi, H., Sen, T., et al. (2022) · Cancer Science · doi:10.1111/cas.15579 · Cited by 15
PI3Kβ inhibition enhances ALK ‐inhibitor sensitivity in ALK ‐rearranged lung cancer
Talwelkar, S. S., Mäyränpää, M. I., Schüler, J. B., Linnavirta, N., Hemmes, A., Adinolfi, S., Kankainen, M., Sommergruber, W., Levonen, A., Räsänen, J. V., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13342 · Cited by 15
LTK and ALK promote neuronal polarity and cortical migration by inhibiting IGF1R activity
Christova, T. Y., Ho, S. K., Liu, Y., Gill, M. K., & Attisano, L. (2023) · EMBO Reports · doi:10.15252/embr.202356937 · Cited by 15
Peng, Y., & Tan, J. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2808163 · Cited by 15
Kumar, R. D., & Bose, R. (2017) · Scientific Reports · doi:10.1038/s41598-017-06366-x · Cited by 14
Jiang, W., He, J., Lv, B., Xi, X., He, G., & He, J. (2020) · PubMed · doi:10.14670/hh-18-183 · Cited by 14
Farnworth, S. L., Barth, N. D., Melville, L. A., Paterson, M., Lynch, C., Holland, P. J., Dransfield, I., & Gregory, C. D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01759 · Cited by 14
Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy
Jóri, B., Falk, M., Hövel, I., Weist, P., Tiemann, M., Heukamp, L. C., & Griesinger, F. (2022) · Current Oncology · doi:10.3390/curroncol29090520 · Cited by 14
EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer
Stone, A. (2014) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.1000173 · Cited by 13
Cardiovascular Adverse Effects of Targeted Antiangiogenic Drugs: Mechanisms and Management
Sundararajan, S., Kumar, A., Poongkunran, M., Kannan, A., & Vogelzang, N. J. (2016) · Future Oncology · doi:10.2217/fon.16.4 · Cited by 13
JAK1 somatic mutation in a myeloproliferative neoplasm
Arulogun, S. O., Choong, H.-L., Taylor, D., Ambrosoli, P., Magor, G. W., Irving, I., Keng, T. B., & Perkins, A. C. (2017) · Haematologica · doi:10.3324/haematol.2017.170266 · Cited by 13
Structural Alterations in Human Fibroblast Growth Factor Receptors in Carcinogenesis
Mikhaylenko, D. S., Alekseev, B. Y., Zaletaev, D. V., et al. (2018) · Biochemistry (Moscow) · doi:10.1134/s0006297918080059 · Cited by 13
Cited by
Targeting PP2A in cancer: an underrated option
Sarais, F., Krempien, F., Koehn, C., Brewing, L., Classen, C. F., Walter, M., & Shokraie, O. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03560-y · Cited by 8
Metadata
- Authors
- Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-08-14
- Volume
- 9
- Issue
- 1
- Pages
- 201-201
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4401593620
- Cited by
- 260
- References
- 859
- FWCI
- 68.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.